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Abstract
Background: Viral hemorrhagic fevers (VHF) are considered to be a serious threat to public health worldwide with up to 100
million cases annually. The general hypothesis is that disseminated intravascular coagulation (DIC) is an important part of
the pathogenesis. The study objectives were to study the variability of DIC in consecutive patients with acute hemorrhagic
fever with renal syndrome (HFRS), and to evaluate if different established DIC-scores can be used as a prognostic marker for
a more severe illness.
Method and Findings: In a prospective study 2006–2008, data from 106 patients with confirmed HFRS were analyzed and
scored for the presence of DIC according to six different templates based on criteria from the International Society on
Thrombosis and Haemostasis (ISTH). The DIC-scoring templates with a fibrinogen/CRP-ratio were most predictive, with
predictions for moderate/severe illness (p,0.01) and bleeding of moderate/major importance (p,0.05). With these
templates, 18.9–28.3% of the patients were diagnosed with DIC.
Conclusions: DIC was found in about one fourth of the patients and correlated with a more severe disease. This supports
that DIC is an important part of the pathogenesis in HFRS. ISTH-scores including fibrinogen/CRP-ratio outperform models
without. The high negative predictive value could be a valuable tool for the clinician. We also believe that our findings could
be relevant for other VHFs.
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Introduction
The term viral hemorrhagic fever (VHF) constitutes disease
caused by a diverse group of highly pathogenic RNA viruses from
four taxonomic families: Arenaviridae, Bunyaviridae, Filoviridae and
Flaviviridae [1,2]. As a group, VHFs are annually estimated to cause
50–100 million cases of illness of various severity worldwide [3].
Dengue virus (Flaviviridae), is responsible for the absolute majority
of these cases [4]. Most VHFs are arthropod borne zoonoses and
have, due to e.g. climate changes and land use, been reported as
emerging. This poses a serious threat to public health in endemic
areas [4]. Common features for VHFs are fever, malaise and a
propensity for bleeding, thrombosis and shock [5]. The severity of
VHF infections varies within the extremes. Case-fatality rates in
up to 90% are shown among those infected with Ebola and
Marburg virus (Filoviridae) [6,7]. Hantaviruses (Bunyaviridae) are
carried by rodents and transmission to humans is caused by
inhalation of infected rodent excreta. Hantaviral infections cause
two different febrile illnesses in human, hemorrhagic fever with
renal syndrome (HFRS) in Eurasia and the more severe hantavirus
cardiopulmonary syndrome in the Americas. It has been estimated
that 250.000–300.000 cases occur annually [8]. Depending on the
causative virus, different hantaviruses have a reported mortality
varying between 0.5–40% [8,9,10,11].
Puumala virus, genus Hantavirus, is the causative agent for the
HFRS in the present study. This virus is endemic in Europe and
causes a mild form of HFRS, also denoted nephropathia
epidemica (NE) which has a lower mortality [10,12]. Besides
symptoms mentioned for VHFs as a group, HFRS commonly
show renal impairment and transient thrombocytopenia is often
diagnostic for the disease [13,14]. Mechanisms for thrombocyto-
penia has been discussed, such as interaction between hantavirus
and platelets or hantavirus and megakaryocytes [9,15,16].
Bleeding of moderate/major importance has been reported in
up 5% of the patients infected with Puumala hantavirus [13]. The
mechanisms behind the pathogenesis of acute VHF are complex
and partly unknown. The ability to infect endothelial cells is
considered a key role in developing HFRS and the hallmark of
hantaviral diseases is altered vascular function and capillary
leakage, ultimately leading to fatal hypotensive shock in severe
cases [9,17,18]. Infection of the endothelial cells is suggested to
cause some tissue damage [19], but unlikely to be the primary
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In addition, inflammation normally shifts the haemostatic system in
favor of thrombosis by multiple mechanisms [21]. These changes in
coagulation may range from limited laboratory deviations to
disseminated intravascular coagulation (DIC), a syndrome with
various degree of microvascular thrombi, thrombocytopenia, and
hemorrhage that may cause failure of the microvasculature and
contribute to organ dysfunction [22,23]. It has earlier been discussed
that the bleeding diathesis in VHF patients may be caused by defect
platelet function and DIC has been observed [24,25,26]. Similarly,
earlier reports suggest that some patients with HFRS present signs of
DIC [27,28,29,30,31,32,33,34]. Today the treatment of HFRS is
symptomatic with dialysis in some selected cases and as for most
VHFs, no useful prognostic marker for severe infection is available at
present [5,9].
To standardize and facilitate the diagnosis of DIC by a
practical, reproducible and flexible diagnostic criteria, a commit-
tee within the International Society on Thrombosis and
Haemostasis (ISTH) developed two separate scoring systems in
2001 [35]. These scoring templates are based on a combination of
readily available laboratory coagulation tests and were designed to
define the two proposed delinineated phases of the condition, i.e.
non-overt DIC, with haemostatic dysfunction but still a compen-
sated coagulation system, and overt DIC, with a decompensated
coagulation system. Earlier studies have shown the overt DIC
template to have high sensitivity and specificity for DIC [36], and
also that replacing fibrinogen with a fibrinogen/CRP-ratio further
enhanced the diagnostic and prognostic power of the template
[37]. Recently, Laine et al. showed that 5 out of 19 patients with
NE fulfilled the criteria for DIC according to ISTH [38].
In a recent, large outbreak of HFRS in northern Sweden [39]
we experienced that several patients became critically ill with
thromboembolic complications and/or life threatening bleedings.
Our hypotheses were that these patients meet international criteria
for DIC, and that the presence of DIC could be used as a
prognostic marker for disease severity.
Materials and Methods
Ethics Statement
The study was approved by the Research Ethics Committee of
Umea ˚ University, Umea ˚, Sweden. Informed written consent was
obtained from all patients.
Subjects
Patients (n=119) with confirmed HFRS, either admitted to the
Clinicof InfectiousDiseases at Umea ˚ University Hospitalor seen by
the on-call doctor and later followed policlinically, were included
consecutively during September 2006 to June 2008. The diagnosis
of HFRS was based upon typical clinical manifestations, e.g. fever,
malaise, thrombocytopenia, and proteinuria, and confirmed by
Puumala virus specific IgM and IgG antibodies as detected by
immunofluorescence assay. Patients admitted late in the course of
infection or patients with missing laboratory data that could not be
scored for the presence of DIC within 12 days from onset of
symptoms were excluded (n=13). After exclusion, data from 106
patients were available for further analysis. The median age of the
subjects was 53 y (range 20–83 y) and 58 (54.7%) were female.
Criteria for moderate/severe illness
Patients were divided into two groups; mild respectively
moderate/severe illness. Patients meeting two or more of the
following criteria were considered to have a moderate/severe
illness: treated in the intensive care unit (ICU), dialysis,
Table 1. Scoring templates for overt- and non-overt (NO) disseminated intravascular coagulation (DIC) in patients with
hemorrhagic fever with renal syndrome.
Score DIC1 DIC2 DIC3
a DIC4
b Score NO-DIC1 NO-DIC2
Platelet count, 10
9/L 2 ,50 ,50 ,50 ,50 1 ,100
1 50–100 50–100 50–100 50–100 0 .100
0 .100 .100 .100 .100
D-dimer, mg/L 3 .2.0 .2.48 .2.0 .2.48 1 $0.2 $0.64
2 0.2–2.0 0.64–2.48 0.2–2.0 0.64–2.48 0 ,0.2 ,0.64
0 ,0.2 ,0.64 ,0.2 ,0.64
PK-INR
c 2 .1.4 .1.4 .1.4 .1.4 1 $1.2
1 1.2–1.4 1.2–1.4 1.2–1.4 1.2–1.4 0 ,1.2
0 ,1.2 ,1.2 ,1.2 ,1.2
Fibrinogen, g/L 1 ,1.0 ,1.0
0 $1.0 $1.0
Fibrinogen/CRP-ratio 1 ,104 ,104 Falling values add 1 point and rising
0 $104 $104 values subtract 1 point for PK and
D-dimer (vice versa for platelets)
DIC1 and NO-DIC1 correspond to standard ISTH scoring using local decision limit. DIC—2 and NO-DIC-2 uses D-dimer cut-offs based on ICU-patients. DIC3-4 are
corrected with a fibrinogen/CRP-ratio instead of fibrinogen.
The original ISTH SSC template uses ‘‘moderately’’ and ‘‘strongly’’ increased values for D-dimer cutoffs [35]. In this table laboratory cutoffs are set from local decision
limits and also corrected with a fibrinogen/CRP ratio [37]. Overt DIC-score $5p: compatible with overt DIC, ,5p: suggestive for non-overt DIC.
aD-dimer cutoff as in DIC1, fibrinogen corrected with fibrinogen/CRP-ratio.
bD-dimer cutoff as in DIC2, fibrinogen corrected with fibrinogen/CRP-ratio.
cPK-INR ,1.2 was equal to PT-prolongation ,3 sec, a value between 1.2 and 1.4 was equal to PT-prolongation .3 but ,6 sec, and values .1.4 were equal to PT-
prolongation .6 sec.
doi:10.1371/journal.pone.0021134.t001
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moderate/severe hypotension (systolic blood pressure #90 mmHg
and intravenous fluid treatment at any given time during
hospitalization), and bleeding of moderate/major importance,
i.e. gastrointestinal bleeding, macroscopic hematuria, and metror-
rhagia.
DIC-scoring according to ISTH
All patients were scored on days with sufficient laboratory data
and the presence of overt and non-overt DIC was defined as a score
of$5 points [35,40].The non-overtDIC scoring templateuses both
major criteria; abnormal levels of fibrin degradation products (D-
dimer), platelet count, prothrombin time (PT), and minor criteria;
e.g. antithrombin and Protein-C. The non-overt DIC scoring
template focuses on repetitive tests and trends to facilitate early
intervention. When using only the major criteria for non-overt DIC,
sufficient robustness was achieved for detecting hemostatic dysfunc-
tion that had a prognostic significance in unselected severely ill
patients [40]. In addition to the major criteria used in the non-overt
DIC template, the overt DIC template also uses fibrinogen, an acute
phase reactant that is almost always elevated in patients with
infection and/or inflammation [41]. The ISTH scoring table has set
values for platelet count, PT and fibrinogen but uses ‘‘moderately’’
and ‘‘strongly’’ increased values for D-dimer. The original ISTH
overt DIC-scoring template allows a choice of two different models
based on D-dimer cut-offs [42]. Correction for fibrinogen/CRP-
ratio has been suggested and was included [37]. This gave us four
different overt DIC templates (DIC 1–4, Table 1). DIC 1 and 3 were
variants which used the local decision limit for D-dimer (0.2 mg/L)
for ‘‘moderately’’, and ten times this value (2.0 mg/L) for ‘‘strongly’’
elevated D-dimer [43]. Cut-offs for DIC 2 and 4 were based on all
D-dimer tests taken in the ICU over 20 months (n=3980). The 25
th
and 75
th percentiles (0.64 and 2.48 mg/L) were used for moderately
and strongly elevated D-dimer in these templates [44]. PT was
converted to PK-INR in our scoring. The same cut-offs for D-dimer
and PK was applied when modifying the original non-overt DIC
templateinto2non-overtDICtemplates(NODIC1and2,Table1).
Blood Samples and Assays
Peripheral blood was drawn in commercially available vacutai-
ners (Becton Dickinson, Franklin Lakes, NJ, USA). Platelet counts
were performed on EDTA-anticoagulated blood on a hematology
analyzer, XE-2100, and blood collected in sodium citrated tubes
was analyzed for D-dimer, fibrinogen and PK-INR on a CA7000
(both Sysmex, Kobe, Japan). Creatinine and C-reactive protein
(CRP) were measured on blood collected in serum separator test
tubes on a Vitros 5.1 automated analyzer (Ortho-Clinical
Diagnostics, Inc., Rochester, NY, USA). Puumala virus specific
IgM and IgG antibodies were measured in serum using an
immunofluorescence assay as previously described [45].
Statistical Analysis
Statistical analyses were performed using SPSS for Windows,
version 16.0 (SPSS Inc., Chicago, IL, USA). Fischer exact test and
x
2 test were used for categorical variables. Mann-Whitney U test
was used for continuous non-normally distributed variables and all
Table 2. Comparison of laboratory and clinical parameters in patients with moderate/severe vs. mild hemorrhagic fever with renal
syndrome.
All (n=106) Moderate/severe illness, (n=13) Mild illness (n=93) p value
a
Age, years
b 53 (40–64) 64 (55–74.5) 51 (38.5–51.5) 0.011
Gender, female/male, n (%) 58/48 (54.7/45.3) 7/6 (53.8/46.2) 51/42 (54.8/45.2) 0.946
Laboratory data at score
c
Platelet count, 6109/L 95 (17–404) 38 (17–268) 100 (19–404) 0.001
D-dimer, mg/L 0.70 (0.12–5.31) 0.90 (0.61–5.31) 0.66 (0.12–3.69) 0.021
PK-INR 1.1 (0.9–1.5) 1.1 (0.9–1.5) 1.0 (0.9–1.4) 0.041
Fibrinogen, g/L 4.66 (1.57–32.0) 4.02 (1.57–8.42) 4.66 (2.25–32.0) 0.137
Fibrinogen/CRP ratio 83.2 (16.4–538.6) 68.6 (28.3–162.0) 85.0 (16.4–538.6) 0.242
CRP, mg/L 57 (7–236) 56 (29–169) 58 (7–236) 0.686
Creatinine, mmol/L 133 (37–1548) 245 (67–1034) 126 (37–1548) 0.010
Clinical data, n (%)
Mild bleeding 27 (25.5) 3 (23.1) 24 (25.8) 0.833
Moderate/severe bleeding 9 (8.5) 3 (23.1) 6 (6.5) 0.045
Need for intensive care 5 (4.7) 5 (38.5) 0 ,0.001
Dialysis 1 (0.9) 1 (7.7) 0 0.007
Thrombosis 3 (2.8) 3 (23.1) 0 ,0.001
Need for oxygen 15 (14.2) 9 (69.2) 6 (6.5) ,0.001
Thrombocyte transfusion 11 (10.4) 5 (38.5) 6 (6.5) ,0.001
Days at hospital, n
d 3 (0–55) 11 (4–55) 3 (0–13) ,0.001
Systolic blood pressure, mmHg
e 120 (80–180) 110 (80–160) 120 (90–180) 0.085
aCalculated using Mann-Whitney U and x
2 test.
bValue given as median, 25
th and 75
th percentiles within parentheses.
cValue given as median, range within parentheses.
dValue given as median, range within parentheses.
eMedian value at the day of DIC-scoring (n=88).
doi:10.1371/journal.pone.0021134.t002
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available DIC-score, and also the highest score was used. In cases
with the same DIC-scores on several occasions, the first score after
onset of symptoms was used. Logistic regression models were used
to determine odds ratios. Performance of the different scoring
systems was tested with receiver operating characteristic curves
(ROC) and quantified by calculating the area under the curve
(AUC) and 95% confidence interval (CI). Two-sided p val-
ues,0.05 was considered statistical significant. Statistics are based
on the highest available DIC-score unless otherwise stated.
Results
Patient description
Patient characteristics are summarized in Table 2. Bleeding of
moderate/major importance was recorded in 8.5% of the patients.
Moderate/severe illness was found in 13 patients (12.3%). These
patients were older compared to those with mild illness and no
gender difference was seen. The moderate/severe ill also had
generally higher creatinine, D-dimer and a lower nadir platelet
count. They were also all admitted to the hospital, required longer
hospitalization and suffered more from bleeding of moderate/
major importance. All radiologically verified venous thrombosis
(n=3), i.e. pulmonary embolism, thrombosis of the porta/
mesenterica veins and thrombosis of the lower extremities, were
found in this group. All cases of thrombosis were diagnosed after
the acute phase of the disease. They all had a nadir platelet count
,50610
9/L during the acute phase. One patient with thrombosis
also developed bleeding of moderate/major importance. All
patients who developed moderate/major bleeding had, compared
to patients who did not, a nadir platelet count of ,150610
9/L.
DIC-scoring templates
Laboratory findings and overt DIC-score kinetics during the
natural course of the infection in the 106 cases are depicted in
Figure 1a and 1b. The first available overt DIC-score and also the
highest score both occurred on a median of day six after onset of
symptoms. Depending on the template used for overt DIC
(Table 1), between 3.8 to 23.6% of the patients met the criteria
($5 points) for overt DIC with their first available score. Using the
highest score during the acute phase, frequencies increased to
between 5.7 to 28.3% (Table 3).
Patients with $5 points were also more often moderate/severe
ill, suffered from bleeding of moderate/severe importance, and
according to overt DIC templates 1, 2 and 4 also more often
required ICU-care (Table 3). Creatinine levels did not differ
between the groups with and without overt DIC (data not shown).
For non-overt DIC template 1 and 2, patients with a cumulative
score $5 points were more often found to be moderate/severe ill
(x
2-test, p,0.01, Table 3). Patients with $5 points in overt DIC
template 3 and 4 were significantly older compared to those below
(median age DIC3 49 y vs. 59 y, p=0.034 and DIC4 49 y vs.
61 y, p=0.011), but no differences were seen for overt DIC
templates 1 and 2. No gender difference was seen for either DIC
template.
The sensitivity, specificity, positive predictive value and negative
predictive value of the templates for moderate/severe illness are
presented in Table 4. ROC analysis of the scores for overt DIC
$5 points compared to those below showed that only template 3
and 4 including the fibrinogen/CRP-ratio were predictive of
moderate/severe illness. They also had higher negative predictive
values. For non-overt DIC, both templates were predictive.
Discussion
In this study we systematically investigated the presence of overt
and non-overt DIC using internationally accepted scoring criteria
in patients with confirmed HFRS. We also wanted to test if this
could be used as a prognostic marker for disease severity. Our
main findings are that DIC-scoring templates modified with a
fibrinogen/CRP-ratio proved to be predictive and prognostic for
moderate/severe illness. Using these templates, depending on the
D-dimer cut off, 18.9 vs. 28.3% of the patients met the criteria for
overt DIC.
In HFRS renal failure is frequent and the level of creatinine has
earlier been used as a marker for clinical severity [14,46]. A
hypothesis is that in severe disease, microthrombosis in the vast
microvascular beds of the kidneys, spleen, liver, and other vital
organs causes organ failure. The formation of microthrombi
consumes platelets and causes elevated D-dimer values, resulting
Figure 1. Descriptive data on 106 consecutive patients with
hemorrhagic fever with renal syndrome. Figure 1a represents
median laboratory data and Figure 1b represents mean overt DIC-score.
doi:10.1371/journal.pone.0021134.g001
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significantly more signs of marked capillary leakage at admission,
i.e. hemoconcentration, moderate/severe hypotension and need for
fluid treatment. Allthese findings areknown complications ofsevere
HFRS. In a recent review on symptoms, signs and severity of NE in
paediatric and adult patients, the authors found severe complica-
tions such as serious internal bleeding and multi organ failure only
in adult patients. Laboratory deviations such as creatinine and CRP
were also significantly higher in the adults [47]. These findings are
in line with ours, where patients with a more severe clinical picture
were significantly older than patients with a milder clinical picture.
A low nadir platelet count and also a large drop in platelet count
have earlier been shown to be an independent predictor for a poor
vital outcome in an unsorted material of adult ICU patients and
predict acute renal failure in nephropathia epidemica patients
[14,22,48]. We could not confirm the relationship between a low
nadir platelet count and acute renal failure in our study (data not
shown).
The ISTH DIC-scoring has earlier been found useful in
identifying patients with suspected DIC [37], and especially in
ICU patients [40,49,50]. Sepsis has been proposed to be the most
frequent cause of DIC with a high mortality [51]. We adjusted the
templates according to local laboratory cutoff levels in line with
earlier studies [42]. HFRS patients have earlier been proposed to
develop DIC on a combination on clinical findings and laboratory
data. The frequency of suggested DIC in these studies has ranged
from a few percent up to 27% [27,52]. The recent study by Laine
et al. using the ISTH-criteria showed DIC in 26%, however this
was not associated with clinical variables and failed to predict
clinical outcome [38]. In the present study, up to 28.3% of the
patients met criteria for overt DIC, which significantly correlated
to moderate/severe illness. The difference in frequency of DIC in
our study, compared to previous studies, could be explained by the
earlier variations in the literature in defining the presence of DIC.
Table 3. Comparison between patient complications and presence of DIC according to overt- and non-overt DIC-score ($5p and
,5p respectively).
Overt DIC n (%) Moderate/severe illness, n (%) Bleeding
a, n (%) Intensive care, n (%)
All 106 13(12.3) 9(8.5) 5(4.7)
DIC1 $5p 8 (7.5) 4(50.0) 4(50.0) 3(37.5)
,5p 98 (92.5) 9(9.2) 5(5.1) 2(2.0)
p value
b 0.008 0.002 0.003
DIC2 $5p 6 (5.7) 4(66.7) 3(50.0) 3(50.0)
,5p 100 (94.3) 9(9.0) 6(6.0) 2(2.0)
p value
b 0.002 0.008 0.001
DIC3 $5p 30 (28.3) 9(30.0) 6(20.0) 3(10.0)
,5p 76 (71.7) 4(5.3) 3(3.9) 2(2.6)
p value
b 0.001 0.015 0.136
DIC4 $5p 20 (18.9) 9(45.0) 5(25.0) 3(15.0)
,5p 86 (81.9) 4(4.7) 4(4.7) 2(2.3)
p value
b ,0.001 0.011 0.045
Non-Overt DIC
All 106 13(12.3) 9(8.5) 5(4.7)
DIC 1 $5p 28 (26.4) 8(28.6) 5(17.9) 5(17.9)
,5p 78 (73.6) 5(6.4) 4(5.1) 0
p value
b 0.005 0.053 0.001
DIC 2 $5p 25 (23.6) 7(28.0) 5(20.0) 4(16.0)
,5p 81 (76.4) 6(7.4) 4(4.9) 1(1.2)
p value
b 0.012 0.032 0.011
aBleeding of moderate/major importance.
bComparison between $5a n d,5 points. P-value calculated with Fischer exact test and x
2 test.
doi:10.1371/journal.pone.0021134.t003
Table 4. Predictive values and calculated area under the
curve (AUC) from receiver operating characteristic curves
(ROC) of overt and non-overt DIC-templates vs. moderate/
severe illness.
Sensitivity Specificity PPV NPV AUC
a p-value
b
Overt
DIC1 30.8 95.7 50.0 91.8 0.63 0.123
DIC2 30.8 97.8 66.7 91.0 0.64 0.096
DIC3 69.2 77.4 30.0 94.7 0.73 0.007
DIC4 69.2 88.2 45.0 95.3 0.79 0.001
Non-overt
DIC1 61.5 79.4 28.6 93.9 0.71 0.017
DIC2 53.8 81.4 28.0 92.9 0.68 0.039
Sensitivity, specificity, positive predictive value (PPV) and negative predictive
value (NPV) are all presented as percentages.
aAUC, comparison between $5p and ,5p.
bp-value for calculated AUC in predicting moderate/severe illness (ROC-
analysis).
doi:10.1371/journal.pone.0021134.t004
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dimer decision limit for exclusion of venous thromboembolism.
The ISTH overt DIC template has earlier been proposed to
miss the diagnosis of early phase of overt DIC (pre-DIC) [36,53],
whereas the ISTH non-overt DIC template has been proposed to
identify patients at risk for developing DIC early. Recent studies
with modifications to the ISTH non-overt DIC scoring show
added prediction of poor outcome in patients with sepsis with an
addition of an organ system failure scoring, but also discrepancy in
the usefulness of added molecular haemostatic markers such as
antithrombin [51,53]. In our study, the trend, although not
significant, was that patients received their highest score somewhat
earlier with the non-overt template. When using the non-overt
DIC template, obvious difficulties occurred interpreting what was
considered a rise or fall in laboratory data. Compared to the overt
DIC templates with a fibrinogen/CRP-ratio, the non-overt DIC
templates performed on par or worse with no added diagnostic
value. Recent studies on unsorted patients with underlying
conditions related to DIC have evaluated different modifications
to the ISTH DIC scoring [36,51,53]. In comparison with other
accepted scoring criteria for DIC, ISTH overt-DIC diagnostic
criteria displayed a high specificity for DIC, was related to a poor
patient outcome, and showed high number of associations with
DIC in infectious disease [36]. With the added fibrinogen/CRP-
ratio in our study, the sensitivity for moderate/severe illness
doubled, allowing a better chance of monitoring patients at risk.
Despite ongoing studies on the use of steroids and antiviral
drugs in VHF, no specific treatment is available today for HFRS.
This makes a useful predictive tool for more severe illness even
more valuable in finding patients who need early and aggressive
symptomatic treatment. The overt-DIC scoring templates using a
fibrinogen/CRP-ratio were found to identify patients at risk for
developing a more severe illness. However, it is also important to
prove that identifying and treating DIC improves clinical
outcome. This needs to be evaluated further in larger patient
samples and HFRS caused by other hantaviruses.
A limitation of this study on patients referred to the hospital is
that many of them were considered to be moderate/severe ill
already at presentation, i.e. before the first possible DIC score.
Hence, the predictive value of the scoring systems is somewhat
biased. The first and also the highest DIC score occurred on the
same day in most of the cases, resulting in just slightly worse
prognostic power for moderate/severe illness for the first available
score. A major advantage is that the templates used are based
solely on readily available coagulation tests. Thus, the templates
may easily be applied in clinical routine.
In conclusion, a high proportion of patients with a mild HFRS
meet the international criteria for overt DIC which increases the
risk for more severe illness. It is crucial to select the best possible
model for DIC-scoring. ISTH-scores including fibrinogen/CRP-
ratio outperform models without. The high negative predictive
value could be a valuable tool for the clinician.
We also believe that our findings could be relevant for other
VHFs.
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